ArticleCell communication and signaling : CCS2025
The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities.Journal of hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDelivery of biologic therapeutics to the central nervous system (CNS) is hindered by the blood-brain barrier (BBB), which restricts large molecule passage. Receptor-mediated transcytosis via transferrin receptor 1 (TfR1) provides a physiological route for selective BBB transport. This study aimed to develop human-specific nanobodies that engage TfR1 without disrupting transferrin function, enabling safe and efficient CNS delivery of therapeutic biologics.
methodsSingle-domain camelid antibodies targeting human TfR1 were isolated, humanized, and optimized through computational and artificial intelligence-guided algorithms to improve humanness, solubility, and stability. Binding kinetics were quantified by surface plasmon resonance using a 1:1 Langmuir model. In vivo BBB permeability and safety were assessed in rats genetically humanized for TfR1 and transferrin following intravenous or subcutaneous administration.
resultsOptimized TfR1-binding nanobodies exhibited high affinity for human TfR1, with equilibrium dissociation constants (KD) in the picomolar range. These nanobodies crossed the BBB efficiently without interfering with transferrin binding or iron homeostasis and were therefore designated NewroBus. When fused to humanized tumor necrosis factor alpha (TNFα)-neutralizing nanobodies, NewroBus heterodimers maintained BBB permeability and achieved sustained cerebrospinal fluid and serum levels for at least three days after subcutaneous dosing. Chronic administration of representative constructs in humanized rats did not alter hematologic parameters, indicating absence of TfR1-related hematotoxicity.
conclusionsHumanized TfR1 nanobodies (NewroBus) enable efficient, TfR1-dependent transcytosis of biologics across the BBB while preserving iron transport and safety. Their high binding affinity, favorable pharmacokinetic properties, and modular fusion capacity position NewroBus as a versatile platform for CNS delivery of therapeutic proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.